Novartis Venture Fund
Dr. Campbell Murray is a Managing Director of the Novartis Venture Funds in Cambridge, MA. He serves serves on the boards of Aerpio Therapeutics, Akebia Therapeutics, √Ç¬≠Alios BioPharm, Euthymics Biosciences, Galera, ImaginAB, Neurovance and Tokai Pharmaceuticals and as an observer on the board of Aileron Therapeutics.
Prior to joining the venture fund in 2005, he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects, reporting to the president & CEO. He held earlier positions at Novartis AG and at McKinsey & Co.
Campbell started his career as a physician in New Zealand, with additional time in the UK and South Africa.
Education, Personal, and Fellowship
Campbell received his Bachelor's in human biology as well as his MD from the University of Auckland. He holds an MBA from Harvard Business School and an Master of Public Policy from the John F. Kennedy School of Government.
Campbell is a member of Kauffman Fellows Class 11 and served his fellowship under mentor Reinhard Ambros at the Novartis Venture Fund in Boston, MA and in Basel, Switzerland.